You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

26 Results
Guidelines and Advice
Status: Current
ID: PET 6
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 5
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Mar 2009
Guidelines and Advice
Status: Archived
ID: 3-16
Jul 2009
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-04-V2
Version: 2
Jan 2009
Guidelines and Advice
Jan 2009
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Adjuvant
Dec 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
Dec 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    dexamethasone
Dec 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
Dec 2021

Pages